Ticker Details
ADMA Biologics Inc ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases.
IPO Date:	October 18, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.5B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.17 | 2.74%
Avg Daily Range (30 D):	$0.40 | 3.30%
Avg Daily Range (90 D):	$0.37 | 2.47%

Institutional Daily Volume
Avg Daily Volume:	1.71M
Avg Daily Volume (30 D):	6.94M
Avg Daily Volume (90 D):	3.75M

Trade Size
Avg Trade Size (Sh.):	173
Avg Trade Size (Sh.) (30 D):	115
Avg Trade Size (Sh.) (90 D):	101

Institutional Trades
Total Institutional Trades:	2,294
Avg Institutional Trade:	$3.49M
Avg Institutional Trade (30 D):	$4.97M
Avg Institutional Trade (90 D):	$4.01M
Avg Institutional Trade Volume:	.31M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.87M
Avg Closing Trade (30 D):	$12.3M
Avg Closing Trade (90 D):	$8.88M
Avg Closing Volume:	517.13K

News

Apr 18, 2026 @ 9:20 PM ADMA Biologics Investor News: If You Have Suffered... Source: The Rosen Law Firm

Apr 10, 2026 @ 7:48 PM ADMA Biologics (NASDAQ: ADMA) Investigated for Pot... Source: Lowey Dannenberg, P.C.

Apr 8, 2026 @ 8:57 PM Bragar Eagel & Squire, P.C. Urges ADMA Biologics, ... Source: Bragar Eagel & Squire, P.C.

Apr 7, 2026 @ 8:59 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: Pomerantz Llp

Apr 3, 2026 @ 10:46 AM $ADMA Stock News: ADMA Biologics Investigated for ... Source: Bleichmar Fonti & Auld Llp

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$.62	$.21	$.62
Diluted EPS	$.6	$.2	$.6
Revenue	$510.17M	$139.16M	$510.17M
Gross Profit	$292.77M	$88.82M	$292.77M
Net Income / Loss	$146.93M	$49.38M	$146.93M
Operating Income / Loss	$191.44M	$62.75M	$191.44M
Cost of Revenue	$217.41M	$50.35M	$217.41M
Net Cash Flow	$-15.52M	$26.25M	$-15.52M
PE Ratio